The global human milk oligosaccharides (HMOs) market was valued at $125.9 million in 2020, and is estimated to reach $332.6 million by 2028, registering a CAGR of 14.1% from 2021 to 2028.
Human milk oligosaccharide (HMO) is a prebiotic, which is essential for the growth and development of infants. It helps to improve the metabolic activity of the digestive system. These prebiotic and antimicrobial functions help in the application of infant formula products.
The major factors that drive the growth of the global HMO market include increase in health consciousness among consumers and surge in consumption of food supplements.
However, the factors such as implementation of stringent government regulations toward production of oligosaccharides and high cost of production hamper the market growth.
HMOs serve as an ideal option for non-lactating mothers, as it contains all of the nutrients that infants need for normal growth. To meet the demand for infant formula ingredients, manufacturers are producing HMOs through various chemical synthesis and fermentation processes.
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
The major functions of HMOs are supply of sialic acids to infants and reduction of influenza infection. Human milk for infants contains higher concentration of oligosaccharides as compared to bovine milk that is obtained from cows. This bovine milk does not contain oligosaccharides that is essential for the development of the infants. Thus, human milk is important for infants, as it contains oligosaccharides for proper maintenance of health.
However, the production of HMOs is difficult due to high cost and lack of availability of enzymes, which are anticipated to hinder the market growth during the forecast period. On the contrary, surge in demand of nutritional foods is projected to offer potential growth opportunities for the global market.
HMOs are important components of breast milk, as they help mother and baby both to fight against certain diseases. This further aids to build strong immune system. However, these HMOs are not present in the breast milk of every mother. Therefore, doctors and scientists produce these kinds of HMOs in laboratories with the help of various processes such as synthetization of enzymes.
HMOs are incorporated in functional food & beverages that promote health with the help of good bacteria, which are essential for the development of infants. Furthermore, they eliminate harmful bacteria such as campylobacter, salmonella, and listeria, thereby boosting their demand.
The global HMO market is segmented into type, application, distribution channel, and region. On the basis of type, the market is categorized into 2’FL, 3’FL, 3’SL, and 6’SL. As per application, it is divided into infant formula, functional food & beverage, and food supplements. According to distribution channel, it is fragmented into hypermarkets & supermarkets, drug store or pharmacy, mass merchandiser, departmental stores, mono-brand stores, specialty stores, and online sales channel. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (the UK, France, the Netherlands, Germany, Turkey, and the rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and the rest of Asia-Pacific), and LAMEA (Brazil, South Africa, the UAE, and the rest of LAMEA).
The major players operating in the global HMO market are Abbott Laboratories, BASF S.E., Biosynth Carbosynth, Chr. Hansen Holding A/S, Dextra Laboratories Ltd., Dupont Nutrition & Biosciences, Elicityl S.A., Glycom A/S, Glycosyn, Inbiose NV, Medolac Laboratories, Neolacta Lifesciences Pvt. Ltd, Nestle Health Science, Royal DSM, and ZuChem.
Human milk oligosaccharide (HMO) is a prebiotic, which is essential for the growth and development of infants. It helps to improve the metabolic activity of the digestive system. These prebiotic and antimicrobial functions help in the application of infant formula products.
The major factors that drive the growth of the global HMO market include increase in health consciousness among consumers and surge in consumption of food supplements.
However, the factors such as implementation of stringent government regulations toward production of oligosaccharides and high cost of production hamper the market growth.
HMOs serve as an ideal option for non-lactating mothers, as it contains all of the nutrients that infants need for normal growth. To meet the demand for infant formula ingredients, manufacturers are producing HMOs through various chemical synthesis and fermentation processes.
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
- wing to the lockdown implemented across various countries, national and international transport have been hampered, which has significantly impacted the supply chains across the globe, thereby increasing the supply–demand gap. All business and production activities have been completely halted, with the exception of those that are absolutely necessary, such as the food and medical sectors, resulting in an economic crisis. Manufacturing and production functions have been stopped, declining the businesses. The HMO market benefited from the COVID-19 pandemic. During the lockdown period, the development of online platforms and e-commerce significantly contributed to revenue generation in the HMO market. However, COVID-19 has created opportunities for many private players to enter the market to meet the increased demand.
The major functions of HMOs are supply of sialic acids to infants and reduction of influenza infection. Human milk for infants contains higher concentration of oligosaccharides as compared to bovine milk that is obtained from cows. This bovine milk does not contain oligosaccharides that is essential for the development of the infants. Thus, human milk is important for infants, as it contains oligosaccharides for proper maintenance of health.
However, the production of HMOs is difficult due to high cost and lack of availability of enzymes, which are anticipated to hinder the market growth during the forecast period. On the contrary, surge in demand of nutritional foods is projected to offer potential growth opportunities for the global market.
HMOs are important components of breast milk, as they help mother and baby both to fight against certain diseases. This further aids to build strong immune system. However, these HMOs are not present in the breast milk of every mother. Therefore, doctors and scientists produce these kinds of HMOs in laboratories with the help of various processes such as synthetization of enzymes.
HMOs are incorporated in functional food & beverages that promote health with the help of good bacteria, which are essential for the development of infants. Furthermore, they eliminate harmful bacteria such as campylobacter, salmonella, and listeria, thereby boosting their demand.
The global HMO market is segmented into type, application, distribution channel, and region. On the basis of type, the market is categorized into 2’FL, 3’FL, 3’SL, and 6’SL. As per application, it is divided into infant formula, functional food & beverage, and food supplements. According to distribution channel, it is fragmented into hypermarkets & supermarkets, drug store or pharmacy, mass merchandiser, departmental stores, mono-brand stores, specialty stores, and online sales channel. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (the UK, France, the Netherlands, Germany, Turkey, and the rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and the rest of Asia-Pacific), and LAMEA (Brazil, South Africa, the UAE, and the rest of LAMEA).
The major players operating in the global HMO market are Abbott Laboratories, BASF S.E., Biosynth Carbosynth, Chr. Hansen Holding A/S, Dextra Laboratories Ltd., Dupont Nutrition & Biosciences, Elicityl S.A., Glycom A/S, Glycosyn, Inbiose NV, Medolac Laboratories, Neolacta Lifesciences Pvt. Ltd, Nestle Health Science, Royal DSM, and ZuChem.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides a quantitative analysis of current trends, estimations, and dynamics of the global HMO market from 2021 to 2028 to identify the prevailing market opportunities.
- Porter’s five forces analysis highlights the potency of the buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier–buyer network.
- In-depth analysis of the market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global industry. The market player positioning segment facilitates benchmarking while providing a clear understanding of the present position of the key market players.
- The report includes analyses of the regional as well as global market, key players, market segments application areas, and growth strategies.
KEY MARKET SEGMENTS
By Type
- 2’FL
- 3’FL
- 3’SL
- 6’SL
By Application
- Infant Formula
- Functional Food & Beverage
- Food Supplements
By Distribution Channel
- Hypermarkets & Supermarkets
- Drug Store or Pharmacy
- Mass Merchandiser
- Departmental Stores
- Mono-brand Stores
- Specialty Stores
- Online Sales Channel
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- France
- Netherlands
- Germany
- Turkey
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa
- UAE
- Rest of LAMEA
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Snapshot
2.2. Key findings
2.2.1. Top investment pocket
2.3. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key forces shaping global human milk oligosaccharides industry/market
3.2.1. Bargaining power of suppliers
3.2.2. Bargaining power of buyers
3.2.3. Threat of new entrants
3.2.4. Threat of substitutes
3.2.5. Intensity of competitive rivalry
3.3. Market dynamics
3.3.1. Drivers
3.3.1.1. Growing acceptance of HMO
3.3.1.2. Increase in demand of HMOs as functional food products
3.3.1.3. Shift towards healthy dietary habits
3.3.2. Restraints
3.3.2.1. High cost of production
3.3.2.2. Health related problems
3.3.3. Opportunities
3.3.3.1. Surge in demand for infant nutrition products
3.3.3.2. Rise in Research & Development (R&D) activities
3.3.4. Impact of COVID-19
3.3.5. Key regulations
CHAPTER 4: GLOBAL HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2.2’FL
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country
4.3.3’FL
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
4.4.3’SL
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country
4.5.6’SL
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast
4.5.3. Market analysis, by country
CHAPTER 5: GLOBAL HUMAN MILK OLIGOSACCHARIDES MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Infant formula
5.2.1. Key market trends, growth factors, and opportunities
5.2.2. Market size and forecast
5.2.3. Market analysis, by country
5.3. Functional food & beverage
5.3.1. Key market trends, growth factors, and opportunities
5.3.2. Market size and forecast
5.3.3. Market analysis, by country
5.4. Food supplements
5.4.1. Key market trends, growth factors, and opportunities
5.4.2. Market size and forecast
5.4.3. Market analysis, by country
CHAPTER 6: GLOBAL HUMAN MILK OLIGOSACCHARIDES MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hypermarkets & Supermarkets
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. Market size and forecast
6.2.3. Market analysis, by country
6.3. Drug store or pharmacy
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Market size and forecast
6.3.3. Market analysis, by country
6.4. Mass merchandiser
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Market size and forecast
6.4.3. Market analysis, by country
6.5. Departmental stores
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. Market size and forecast
6.5.3. Market analysis, by country
6.6. Mono-brand store
6.6.1. Key market trends, growth factors, and opportunities
6.6.2. Market size and forecast
6.6.3. Market analysis, by country
6.7. Specialty stores
6.7.1. Key market trends, growth factors, and opportunities
6.7.2. Market size and forecast
6.7.3. Market analysis, by country
6.8. Online Sales Channel
6.8.1. Key market trends, growth factors, and opportunities
6.8.2. Market size and forecast
6.8.3. Market analysis, by country
CHAPTER 7: HUMAN MILK OLIGOSACCHARIDES MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. Market size and forecast, by Type
7.2.3. Market size and forecast, by Application
7.2.4. Market size and forecast, by distribution channel
7.2.5. Market size and forecast, by Country
7.2.6. U. S.
7.2.6.1. Market size and forecast, By type
7.2.6.2. Market size and forecast, by application
7.2.6.3. Market size and forecast, by distribution channel
7.2.7. CANADA
7.2.7.1. Market size and forecast, By type
7.2.7.2. Market size and forecast, by application
7.2.7.3. Market size and forecast, by distribution channel
7.2.8. MEXICO
7.2.8.1. Market size and forecast, By type
7.2.8.2. Market size and forecast, by application
7.2.8.3. Market size and forecast, by distribution channel
7.3. Europe
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Market size and forecast, by Type
7.3.3. Market size and forecast, by Application
7.3.4. Market size and forecast, by distribution channel
7.3.5. Market size and forecast, by Country
7.3.6. UK
7.3.6.1. Market size and forecast, By type
7.3.6.2. Market size and forecast, by application
7.3.6.3. Market size and forecast, by distribution channel
7.3.7. FRANCE
7.3.7.1. Market size and forecast, By type
7.3.7.2. Market size and forecast, by application
7.3.7.3. Market size and forecast, by distribution channel
7.3.8. NETHERLANDS
7.3.8.1. Market size and forecast, By type
7.3.8.2. Market size and forecast, by application
7.3.8.3. Market size and forecast, by distribution channel
7.3.9. GERMANY
7.3.9.1. Market size and forecast, By type
7.3.9.2. Market size and forecast, by application
7.3.9.3. Market size and forecast, by distribution channel
7.3.10. TURKEY
7.3.10.1. Market size and forecast, By type
7.3.10.2. Market size and forecast, by application
7.3.10.3. Market size and forecast, by distribution channel
7.3.11. REST OF EUROPE
7.3.11.1. Market size and forecast, By type
7.3.11.2. Market size and forecast, by application
7.3.11.3. Market size and forecast, by distribution channel
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Market size and forecast, by Type
7.4.3. Market size and forecast, by Application
7.4.4. Market size and forecast, by distribution channel
7.4.5. Market size and forecast, by Country
7.4.6. CHINA
7.4.6.1. Market size and forecast, By type
7.4.6.2. Market size and forecast, by application
7.4.6.3. Market size and forecast, by distribution channel
7.4.7. JAPAN
7.4.7.1. Market size and forecast, By type
7.4.7.2. Market size and forecast, by application
7.4.7.3. Market size and forecast, by distribution channel
7.4.8. INDIA
7.4.8.1. Market size and forecast, By type
7.4.8.2. Market size and forecast, by application
7.4.8.3. Market size and forecast, by distribution channel
7.4.9. SOUTH KOREA
7.4.9.1. Market size and forecast, By type
7.4.9.2. Market size and forecast, by application
7.4.9.3. Market size and forecast, by distribution channel
7.4.10. AUSTRALIA
7.4.10.1. Market size and forecast, By type
7.4.10.2. Market size and forecast, by application
7.4.10.3. Market size and forecast, by distribution channel
7.4.11. REST OF ASIA-PACIFIC
7.4.11.1. Market size and forecast, By type
7.4.11.2. Market size and forecast, by application
7.4.11.3. Market size and forecast, by distribution channel
7.5. LAMEA
7.5.1. Key market trends, growth factors, and opportunities
7.5.2. Market size and forecast, by Type
7.5.3. Market size and forecast, by Application
7.5.4. Market size and forecast, by distribution channel
7.5.5. Market size and forecast, by Country
7.5.6. BRAZIL
7.5.6.1. Market size and forecast, By type
7.5.6.2. Market size and forecast, by application
7.5.6.3. Market size and forecast, by distribution channel
7.5.7. SOUTH AFRICA
7.5.7.1. Market size and forecast, By type
7.5.7.2. Market size and forecast, by application
7.5.7.3. Market size and forecast, by distribution channel
7.5.8. UNITED ARAB EMIRATES
7.5.8.1. Market size and forecast, By type
7.5.8.2. Market size and forecast, by application
7.5.8.3. Market size and forecast, by distribution channel
7.5.9. REST OF LAMEA
7.5.9.1. Market size and forecast, By type
7.5.9.2. Market size and forecast, by application
7.5.9.3. Market size and forecast, by distribution channel
CHAPTER 8: COMPETITION LANDSCAPE
8.1. Top winning strategies
8.2. Product mapping
8.3. Competitive dashboard
8.4. Competitive heat map
8.5. Key developments
8.5.1. Acquisition
8.5.2. Business Expansion
8.5.3. Product Launch
CHAPTER 9: COMPANY PROFILES
9.1. Biosynth Carbosynth
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Product portfolio
9.2. Chr. Hansen Holding A/S
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. R&D Expenditure
9.2.7. Business performance
9.2.8. Key strategic moves and developments
9.3. Dextra Laboratories Ltd
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Product portfolio
9.4. DuPont Nutrition & Biosciences
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Product portfolio
9.4.5. Key strategic moves and developments
9.5. Elicityl S. A.
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Product portfolio
9.6. Glycosyn
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Product portfolio
9.6.5. Key strategic moves and developments
9.7. Inbiose NV
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Product portfolio
9.8. Medolac Laboratories
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Product portfolio
9.9. Nestle Health Science
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. R&D Expenditure
9.9.7. Business performance
9.10. ROYAL DSM
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. R&D Expenditure
9.10.7. Business performance
9.10.8. Key strategic moves and developmentsLIST OF TABLES
TABLE 01. GLOBAL HUMAN MILK OLIGOSACCHARIDES, MARKET BY TYPE, 2020-2028 ($MILLION)
TABLE 02.2’FL HUMAN MILK OLIGOSACCHARIDES MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 03.3’FL HUMAN MILK OLIGOSACCHARIDES MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 04.3’SL HUMAN MILK OLIGOSACCHARIDES MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 05.6’SL HUMAN MILK OLIGOSACCHARIDES MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 06. GLOBAL HUMAN MILK OLIGOSACCHARIDES MARKET, BY APPLICATION, 2020-2028 ($MILLION)
TABLE 07. HUMAN MILK OLIGOSACCHARIDES MARKET FOR INFANT FORMULA, BY REGION, 2020-2028 ($MILLION)
TABLE 08. HUMAN MILK OLIGOSACCHARIDES MARKET FOR FUNCTIONAL FOOD & BEVERAGE, BY REGION, 2020-2028 ($MILLION)
TABLE 09. HUMAN MILK OLIGOSACCHARIDES MARKET FOR FOOD SUPPLEMENTS, BY REGION, 2020-2028 ($MILLION)
TABLE 10. GLOBAL HUMAN MILK OLIGOSACCHARIDES MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 ($MILLION)
TABLE 11. HUMAN MILK OLIGOSACCHARIDES MARKET FOR HYPERMARKETS & SUPERMARKETS, BY REGION, 2020-2028 ($MILLION)
TABLE 12. HUMAN MILK OLIGOSACCHARIDES MARKET FOR DRU.S.ORE OR PHARMACY, BY REGION, 2020-2028 ($MILLION)
TABLE 13. HUMAN MILK OLIGOSACCHARIDES MARKET FOR MASS MERCHANDISER, BY REGION, 2020-2028 ($MILLION)
TABLE 14. HUMAN MILK OLIGOSACCHARIDES MARKET FOR DEPARTMENTAL STORES, BY REGION, 2020-2028 ($MILLION)
TABLE 15. HUMAN MILK OLIGOSACCHARIDES MARKET FOR MONO-BRAND STORE, BY REGION, 2020-2028 ($MILLION)
TABLE 16. HUMAN MILK OLIGOSACCHARIDES MARKET FOR SPECIALTY STORES, BY REGION, 2020-2028 ($MILLION)
TABLE 17. HUMAN MILK OLIGOSACCHARIDES MARKET FOR ONLINE SALES CHANNEL, BY REGION, 2020-2028 ($MILLION)
TABLE 18. GLOBAL HUMAN MILK OLIGOSACCHARIDES MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 19. NORTH AMERICA HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2020-2028 ($MILLION)
TABLE 20. NORTH AMERICA HUMAN MILK OLIGOSACCHARIDES MARKET, BY APPLICATION, 2020-2028 ($MILLION)
TABLE 21. NORTH AMERICA HUMAN MILK OLIGOSACCHARIDES MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 ($MILLION)
TABLE 22. NORTH AMERICA HUMAN MILK OLIGOSACCHARIDES MARKET, BY COUNTRY, 2020-2028 ($MILLION)
TABLE 23. U.S. HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2020-2028 ($MILLION)
TABLE 24. U.S. HUMAN MILK OLIGOSACCHARIDES MARKET, BY APPLICATION, 2020-2028 ($MILLION)
TABLE 25. U.S. HUMAN MILK OLIGOSACCHARIDES MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 ($MILLION)
TABLE 26. CANADA HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2020-2028 ($MILLION)
TABLE 27. CANADA HUMAN MILK OLIGOSACCHARIDES MARKET, BY APPLICATION, 2020-2028 ($MILLION)
TABLE 28. CANADA HUMAN MILK OLIGOSACCHARIDES MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 ($MILLION)
TABLE 29. MEXICO HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2020-2028 ($MILLION)
TABLE 30. MEXICO HUMAN MILK OLIGOSACCHARIDES MARKET, BY APPLICATION, 2020-2028 ($MILLION)
TABLE 31. MEXICO HUMAN MILK OLIGOSACCHARIDES MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 ($MILLION)
TABLE 32. EUROPE HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2020-2028 ($MILLION)
TABLE 33. EUROPE HUMAN MILK OLIGOSACCHARIDES MARKET, BY APPLICATION, 2020-2028 ($MILLION)
TABLE 34. EUROPE HUMAN MILK OLIGOSACCHARIDES MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 ($MILLION)
TABLE 35. EUROPE HUMAN MILK OLIGOSACCHARIDES MARKET, BY COUNTRY, 2020-2028 ($MILLION)
TABLE 36. UK HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2020-2028 ($MILLION)
TABLE 37. UK HUMAN MILK OLIGOSACCHARIDES MARKET, BY APPLICATION, 2020-2028 ($MILLION)
TABLE 38. UK HUMAN MILK OLIGOSACCHARIDES MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 ($MILLION)
TABLE 39. FRANCE HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2020-2028 ($MILLION)
TABLE 40. FRANCE HUMAN MILK OLIGOSACCHARIDES MARKET, BY APPLICATION, 2020-2028 ($MILLION)
TABLE 41. FRANCE HUMAN MILK OLIGOSACCHARIDES MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 ($MILLION)
TABLE 42. NETHERLANDS HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2020-2028 ($MILLION)
TABLE 43. NETHERLANDS HUMAN MILK OLIGOSACCHARIDES MARKET, BY APPLICATION, 2020-2028 ($MILLION)
TABLE 44. NETHERLANDS HUMAN MILK OLIGOSACCHARIDES MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 ($MILLION)
TABLE 45. GERMANY HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2020-2028 ($MILLION)
TABLE 46. GERMANY HUMAN MILK OLIGOSACCHARIDES MARKET, BY APPLICATION, 2020-2028 ($MILLION)
TABLE 47. GERMANY HUMAN MILK OLIGOSACCHARIDES MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 ($MILLION)
TABLE 48. TURKEY HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2020-2028 ($MILLION)
TABLE 49. TURKEY HUMAN MILK OLIGOSACCHARIDES MARKET, BY APPLICATION, 2020-2028 ($MILLION)
TABLE 50. TURKEY HUMAN MILK OLIGOSACCHARIDES MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 ($MILLION)
TABLE 51. REST OF EUROPE HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2020-2028 ($MILLION)
TABLE 52. REST OF EUROPE HUMAN MILK OLIGOSACCHARIDES MARKET, BY APPLICATION, 2020-2028 ($MILLION)
TABLE 53. REST OF EUROPE HUMAN MILK OLIGOSACCHARIDES MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 ($MILLION)
TABLE 54. ASIA-PACIFIC HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2020-2028 ($MILLION)
TABLE 55. ASIA-PACIFIC HUMAN MILK OLIGOSACCHARIDES MARKET, BY APPLICATION, 2020-2028 ($MILLION)
TABLE 56. ASIA-PACIFIC HUMAN MILK OLIGOSACCHARIDES MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 ($MILLION)
TABLE 57. ASIA-PACIFIC HUMAN MILK OLIGOSACCHARIDES MARKET, BY COUNTRY, 2020-2028 ($MILLION)
TABLE 58. CHINA HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2020-2028 ($MILLION)
TABLE 59. CHINA HUMAN MILK OLIGOSACCHARIDES MARKET, BY APPLICATION, 2020-2028 ($MILLION)
TABLE 60. CHINA HUMAN MILK OLIGOSACCHARIDES MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 ($MILLION)
TABLE 61. JAPAN HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2020-2028 ($MILLION)
TABLE 62. JAPAN HUMAN MILK OLIGOSACCHARIDES MARKET, BY APPLICATION, 2020-2028 ($MILLION)
TABLE 63. JAPAN HUMAN MILK OLIGOSACCHARIDES MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 ($MILLION)
TABLE 64. INDIA HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2020-2028 ($MILLION)
TABLE 65. INDIA HUMAN MILK OLIGOSACCHARIDES MARKET, BY APPLICATION, 2020-2028 ($MILLION)
TABLE 66. INDIA HUMAN MILK OLIGOSACCHARIDES MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 ($MILLION)
TABLE 67. SOUTH KOREA HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2020-2028 ($MILLION)
TABLE 68. SOUTH KOREA HUMAN MILK OLIGOSACCHARIDES MARKET, BY APPLICATION, 2020-2028 ($MILLION)
TABLE 69. SOUTH KOREA HUMAN MILK OLIGOSACCHARIDES MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 ($MILLION)
TABLE 70. AUSTRALIA HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2020-2028 ($MILLION)
TABLE 71. AUSTRALIA HUMAN MILK OLIGOSACCHARIDES MARKET, BY APPLICATION, 2020-2028 ($MILLION)
TABLE 72. AUSTRALIA HUMAN MILK OLIGOSACCHARIDES MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 ($MILLION)
TABLE 73. REST OF ASIA-PACIFIC HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2020-2028 ($MILLION)
TABLE 74. REST OF ASIA-PACIFIC HUMAN MILK OLIGOSACCHARIDES MARKET, BY APPLICATION, 2020-2028 ($MILLION)
TABLE 75. REST OF ASIA-PACIFIC HUMAN MILK OLIGOSACCHARIDES MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 ($MILLION)
TABLE 76. LAMEA HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2020-2028 ($MILLION)
TABLE 77. LAMEA HUMAN MILK OLIGOSACCHARIDES MARKET, BY APPLICATION, 2020-2028 ($MILLION)
TABLE 78. LAMEA HUMAN MILK OLIGOSACCHARIDES MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 ($MILLION)
TABLE 79. LAMEA HUMAN MILK OLIGOSACCHARIDES MARKET, BY COUNTRY, 2020-2028 ($MILLION)
TABLE 80. BRAZIL HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2020-2028 ($MILLION)
TABLE 81. BRAZIL HUMAN MILK OLIGOSACCHARIDES MARKET, BY APPLICATION, 2020-2028 ($MILLION)
TABLE 82. BRAZIL HUMAN MILK OLIGOSACCHARIDES MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 ($MILLION)
TABLE 83. SOUTH AFRICA HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2020-2028 ($MILLION)
TABLE 84. SOUTH AFRICA HUMAN MILK OLIGOSACCHARIDES MARKET, BY APPLICATION, 2020-2028 ($MILLION)
TABLE 85. SOUTH AFRICA HUMAN MILK OLIGOSACCHARIDES MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 ($MILLION)
TABLE 86. UNITED ARAB EMIRATES HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2020-2028 ($MILLION)
TABLE 87. UNITED ARAB EMIRATES HUMAN MILK OLIGOSACCHARIDES MARKET, BY APPLICATION, 2020-2028 ($MILLION)
TABLE 88. UNITED ARAB EMIRATES HUMAN MILK OLIGOSACCHARIDES MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 ($MILLION)
TABLE 89. REST OF LAMEA HUMAN MILK OLIGOSACCHARIDES MARKET, BY TYPE, 2020-2028 ($MILLION)
TABLE 90. REST OF LAMEA HUMAN MILK OLIGOSACCHARIDES MARKET, BY APPLICATION, 2020-2028 ($MILLION)
TABLE 91. REST OF LAMEA HUMAN MILK OLIGOSACCHARIDES MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 ($MILLION)
TABLE 92. BIOSYNTH CARBOSYNTH: KEY EXECUTIVES
TABLE 93. BIOSYNTH CARBOSYNTH: COMPANY SNAPSHOT
TABLE 94. BIOSYNTH CARBOSYNTH: PRODUCT PORTFOLIO
TABLE 95. CHR. HANSEN HOLDING A/S: KEY EXECUTIVES
TABLE 96. CHR. HANSEN HOLDING A/S: COMPANY SNAPSHOT
TABLE 97. CHR. HANSEN HOLDING A/S: OPERATING SEGMENTS
TABLE 98. CHR. HANSEN HOLDING A/S: PRODUCT PORTFOLIO
TABLE 99. CHR. HANSEN HOLDING A/S: R&D EXPENDITURE, 2018-2020 ($MILLION)
TABLE 100. CHR. HANSEN HOLDING A/S: NET SALES, 2018-2020 ($MILLION)
TABLE 101. DEXTRA LABORATORIES LTD: KEY EXECUTIVES
TABLE 102. DEXTRA LABORATORIES LTD: COMPANY SNAPSHOT
TABLE 103. DEXTRA LABORATORIES LTD: PRODUCT PORTFOLIO
TABLE 104. DUPONT NUTRITION BIOSCIENCES: KEY EXECUTIVES
TABLE 105. DUPONT NUTRITION BIOSCIENCES: COMPANY SNAPSHOT
TABLE 106. DUPONT NUTRITION BIOSCIENCES: PRODUCT PORTFOLIO
TABLE 107. ELICITYL S. A.: KEY EXECUTIVES
TABLE 108. ELICITYL S. A.: COMPANY SNAPSHOT
TABLE 109. ELICITYL S. A.: PRODUCT PORTFOLIO
TABLE 110. GLYCOSYN: KEY EXECUTIVES
TABLE 111. GLYCOSYN: COMPANY SNAPSHOT
TABLE 112. GLYCOSYN: PRODUCT PORTFOLIO
TABLE 113. INBIOSE NV: KEY EXECUTIVES
TABLE 114. INBIOSE NV: COMPANY SNAPSHOT
TABLE 115. INBIOSE NV: PRODUCT PORTFOLIO
TABLE 116. MEDOLAC LABORATORIES: KEY EXECUTIVES
TABLE 117. MEDOLAC LABORATORIES: COMPANY SNAPSHOT
TABLE 118. MEDOLAC LABORATORIES: PRODUCT PORTFOLIO
TABLE 119. NESTLE HEALTH SCIENCE: KEY EXECUTIVES
TABLE 120. NESTLE HEALTH SCIENCE: COMPANY SNAPSHOT
TABLE 121. NESTLE HEALTH SCIENCE: OPERATING SEGMENTS
TABLE 122. NESTLE HEALTH SCIENCE: PRODUCT PORTFOLIO
TABLE 123. NESTLE HEALTH SCIENCE: R&D EXPENDITURE, 2018-2020 ($MILLION)
TABLE 124. NESTLE HEALTH SCIENCE: NET SALES, 2018-2020 ($MILLION)
TABLE 125. ROYAL DSM: KEY EXECUTIVES
TABLE 126. ROYAL DSM: COMPANY SNAPSHOT
TABLE 127. ROYAL DSM: OPERATING SEGMENTS
TABLE 128. ROYAL DSM: PRODUCT PORTFOLIO
TABLE 129. ROYAL DSM: R&D EXPENDITURE, 2018-2020 ($MILLION)
TABLE 130. ROYAL DSM: NET SALES, 2018-2020 ($MILLION)LIST OF FIGURES
FIGURE 01. KEY MARKET SEGMENTS
FIGURE 02. GLOBAL HUMAN MILK OLIGOSACCHARIDES MARKET
FIGURE 03. TOP INVESTMENT POCKETS
FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
FIGURE 07. LOW THREAT OF SUBSTITUTES
FIGURE 08. HIGH INTENSITY OF COMPETITIVE RIVALRY
FIGURE 09. GLOBAL HUMAN MILK OLIGOSACCHARIDES MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES, 2020-2028
FIGURE 10. GLOBAL HUMAN MILK OLIGOSACCHARIDES MARKET SHARE, BY TYPE, 2020-2028
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF 2’FL HUMAN MILK OLIGOSACCHARIDES MARKET ($MILLION), BY COUNTRY, 2020 & 2028 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF 3’FL HUMAN MILK OLIGOSACCHARIDES MARKET ($MILLION), BY COUNTRY, 2020 & 2028 (%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF 3’SL HUMAN MILK OLIGOSACCHARIDES MARKET($MILLION), BY COUNTRY, 2020 & 2028 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF 6’SL HUMAN MILK OLIGOSACCHARIDES MARKET ($MILLION), BY COUNTRY, 2020 & 2028 (%)
FIGURE 15. GLOBAL HUMAN MILK OLIGOSACCHARIDES MARKET SHARE, BY APPLICATION, 2020-2028
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF HUMAN MILK OLIGOSACCHARIDES MARKET FOR INFANT FORMULA ($MILLION), BY COUNTRY, 2020 & 2028 (%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF HUMAN MILK OLIGOSACCHARIDES MARKET FOR FUNCTIONAL FOOD & BEVERAGE ($MILLION), BY COUNTRY, 2020 & 2028 (%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF HUMAN MILK OLIGOSACCHARIDES MARKET FOR FOOD SUPPLEMENTS ($MILLION), BY COUNTRY, 2020 & 2028 (%)
FIGURE 19. GLOBAL HUMAN MILK OLIGOSACCHARIDES MARKET SHARE, BY DISTRIBUTION CHANNEL, 2020-2028
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF HUMAN MILK OLIGOSACCHARIDES MARKET FOR HYPERMARKETS & SUPERMARKETS ($MILLION), BY COUNTRY, 2020 & 2028 (%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF HUMAN MILK OLIGOSACCHARIDES MARKET FOR DRU.S.ORE OR PHARMACY ($MILLION), BY COUNTRY, 2020 & 2028 (%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF HUMAN MILK OLIGOSACCHARIDES MARKET FOR MASS MERCHANDISER ($MILLION), BY COUNTRY, 2020 & 2028 (%)
FIGURE 23. COMPARATIVE SHARE ANALYSIS OF HUMAN MILK OLIGOSACCHARIDES MARKET FOR DEPARTMENTAL STORES ($MILLION), BY COUNTRY, 2020 & 2028 (%)
FIGURE 24. COMPARATIVE SHARE ANALYSIS OF HUMAN MILK OLIGOSACCHARIDES MARKET FOR MONO-BRAND STORE ($MILLION), BY COUNTRY, 2020 & 2028 (%)
FIGURE 25. COMPARATIVE SHARE ANALYSIS OF HUMAN MILK OLIGOSACCHARIDES MARKET FOR SPECIALTY STORES ($MILLION), BY COUNTRY, 2020 & 2028 (%)
FIGURE 26. COMPARATIVE SHARE ANALYSIS OF HUMAN MILK OLIGOSACCHARIDES MARKET FOR ONLINE SALES CHANNEL ($MILLION), BY COUNTRY, 2020 & 2028 (%)
FIGURE 27. GLOBAL HUMAN MILK OLIGOSACCHARIDES MARKET SHARE, BY REGION, 2020-2028
FIGURE 28. U.S. HUMAN MILK OLIGOSACCHARIDES MARKET REVENUE, 2020-2028 ($MILLION)
FIGURE 29. CANADA HUMAN MILK OLIGOSACCHARIDES MARKET REVENUE, 2020-2028 ($MILLION)
FIGURE 30. MEXICO HUMAN MILK OLIGOSACCHARIDES MARKET REVENUE, 2020-2028 ($MILLION)
FIGURE 31. UK HUMAN MILK OLIGOSACCHARIDES MARKET REVENUE, 2020-2028 ($MILLION)
FIGURE 32. FRANCE HUMAN MILK OLIGOSACCHARIDES MARKET REVENUE, 2020-2028 ($MILLION)
FIGURE 33. NETHERLANDS HUMAN MILK OLIGOSACCHARIDES MARKET REVENUE, 2020-2028 ($MILLION)
FIGURE 34. GERMANY HUMAN MILK OLIGOSACCHARIDES MARKET REVENUE, 2020-2028 ($MILLION)
FIGURE 35. TURKEY HUMAN MILK OLIGOSACCHARIDES MARKET REVENUE, 2020-2028 ($MILLION)
FIGURE 36. REST OF EUROPE HUMAN MILK OLIGOSACCHARIDES MARKET REVENUE, 2020-2028 ($MILLION)
FIGURE 37. CHINA HUMAN MILK OLIGOSACCHARIDES MARKET REVENUE, 2020-2028 ($MILLION)
FIGURE 38. JAPAN HUMAN MILK OLIGOSACCHARIDES MARKET REVENUE, 2020-2028 ($MILLION)
FIGURE 39. INDIA HUMAN MILK OLIGOSACCHARIDES MARKET REVENUE, 2020-2028 ($MILLION)
FIGURE 40. SOUTH KOREA HUMAN MILK OLIGOSACCHARIDES MARKET REVENUE, 2020-2028 ($MILLION)
FIGURE 41. AUSTRALIA HUMAN MILK OLIGOSACCHARIDES MARKET REVENUE, 2020-2028 ($MILLION)
FIGURE 42. REST OF ASIA-PACIFIC HUMAN MILK OLIGOSACCHARIDES MARKET REVENUE, 2020-2028 ($MILLION)
FIGURE 43. BRAZIL HUMAN MILK OLIGOSACCHARIDES MARKET REVENUE, 2020-2028 ($MILLION)
FIGURE 44. SOUTH AFRICA HUMAN MILK OLIGOSACCHARIDES MARKET REVENUE, 2020-2028 ($MILLION)
FIGURE 45. UNITED ARAB EMIRATES HUMAN MILK OLIGOSACCHARIDES MARKET REVENUE, 2020-2028 ($MILLION)
FIGURE 46. REST OF LAMEA HUMAN MILK OLIGOSACCHARIDES MARKET REVENUE, 2020-2028 ($MILLION)
FIGURE 47. TOP WINNING STRATEGIES, BY YEAR, 2018-2021*
FIGURE 48. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2021* (%)
FIGURE 49. TOP WINNING STRATEGIES, BY COMPANY, 2018-2021*
FIGURE 50. PRODUCT MAPPING OF TOP 10 KEY PLAYERS
FIGURE 51. COMPETITIVE DASHBOARD OF TOP 10 KEY PLAYERS
FIGURE 52. COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 53. CHR. HANSEN HOLDING A/S: R&D EXPENDITURE, 2018-2020 ($MILLION)
FIGURE 54. CHR. HANSEN HOLDING A/S: NET SALES, 2018-2020 ($MILLION)
FIGURE 55. CHR. HANSEN HOLDING A/S: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 56. CHR. HANSEN HOLDING A/S: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 57. NESTLE HEALTH SCIENCE: R&D EXPENDITURE, 2018-2020 ($MILLION)
FIGURE 58. NESTLE HEALTH SCIENCE: NET SALES, 2018-2020 ($MILLION)
FIGURE 59. NESTLE HEALTH SCIENCE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 60. NESTLE HEALTH SCIENCE: REVENUE SHARE BY REGION, 2020(%)
FIGURE 61. ROYAL DSM: R&D EXPENDITURE, 2018-2020 ($MILLION)
FIGURE 62. ROYAL DSM: NET SALES, 2018-2020 ($MILLION)
FIGURE 63. ROYAL DSM: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 64. ROYAL DSM: REVENUE SHARE BY REGION, 2020 (%)
Companies Mentioned
- Abbott Laboratories
- BASF S.E.
- Biosynth Carbosynth
- Chr. Hansen Holding A/S
- Dextra Laboratories Ltd.
- Dupont Nutrition & Biosciences
- Elicityl S.A.
- Glycom A/S
- Glycosyn
- Inbiose NV
- Medolac Laboratories
- Neolacta Lifesciences Pvt. Ltd
- Nestle Health Science
- Royal DSM
- ZuChem.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
